Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) was upgraded by investment analysts at TheStreet from a “c” rating to a “b-” rating in a report released on Monday.

A number of other research analysts also recently commented on AMPH. BMO Capital Markets dropped their price objective on shares of Amphastar Pharmaceuticals from $18.00 to $16.00 and set a “market perform” rating for the company in a research note on Tuesday, March 14th. Jefferies Group LLC set a $21.00 price objective on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, March 14th. Raymond James Financial, Inc. downgraded shares of Amphastar Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and dropped their price objective for the company from $21.00 to $18.00 in a research note on Tuesday, March 14th. Needham & Company LLC dropped their price objective on shares of Amphastar Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, March 14th. Finally, Piper Jaffray Companies dropped their price objective on shares of Amphastar Pharmaceuticals from $22.00 to $20.00 and set an “overweight” rating for the company in a research note on Tuesday, March 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $20.14.

Shares of Amphastar Pharmaceuticals (NASDAQ AMPH) traded up 2.43% on Monday, reaching $17.68. 289,062 shares of the company’s stock traded hands. Amphastar Pharmaceuticals has a 52 week low of $12.05 and a 52 week high of $21.75. The stock’s 50-day moving average price is $16.10 and its 200-day moving average price is $16.25. The stock has a market capitalization of $808.63 million, a price-to-earnings ratio of 93.05 and a beta of 1.68.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Monday, May 8th. The company reported $0.03 EPS for the quarter, missing the Zacks’ consensus estimate of $0.06 by $0.03. Amphastar Pharmaceuticals had a net margin of 3.54% and a return on equity of 2.69%. The company had revenue of $56.67 million for the quarter, compared to analyst estimates of $63.74 million. During the same period in the prior year, the company earned $0.12 EPS. The company’s revenue was down 4.5% compared to the same quarter last year. Equities analysts predict that Amphastar Pharmaceuticals will post $0.40 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/06/28/amphastar-pharmaceuticals-inc-amph-rating-increased-to-b-at-thestreet.html.

In related news, Director Michael A. Zasloff sold 15,000 shares of the stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $17.01, for a total transaction of $255,150.00. Following the completion of the sale, the director now owns 47,411 shares of the company’s stock, valued at approximately $806,461.11. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Richard K. Prins sold 10,000 shares of the stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $17.07, for a total transaction of $170,700.00. Following the sale, the director now directly owns 28,844 shares of the company’s stock, valued at approximately $492,367.08. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 43,982 shares of company stock valued at $735,850. Corporate insiders own 11.10% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the company. Rothschild Asset Management Inc. acquired a new stake in Amphastar Pharmaceuticals during the first quarter worth about $9,056,000. Citadel Advisors LLC increased its stake in Amphastar Pharmaceuticals by 1,823.3% in the first quarter. Citadel Advisors LLC now owns 355,566 shares of the company’s stock worth $5,156,000 after buying an additional 337,079 shares during the period. Dimensional Fund Advisors LP increased its stake in Amphastar Pharmaceuticals by 68.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 800,900 shares of the company’s stock worth $14,753,000 after buying an additional 324,043 shares during the period. Russell Investments Group Ltd. acquired a new stake in Amphastar Pharmaceuticals during the fourth quarter worth about $5,829,000. Finally, State Street Corp increased its stake in Amphastar Pharmaceuticals by 11.1% in the first quarter. State Street Corp now owns 1,062,439 shares of the company’s stock worth $15,406,000 after buying an additional 106,448 shares during the period. 45.41% of the stock is owned by hedge funds and other institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.